Q-omics provides the consensus-scored MIR5700 profile across patient tissues and cancer cell-line models. MIR5700 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR5700 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MIR5700 RNA expression shows 6,155 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, HNSC, and STAD as cancer lineages where MIR5700 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5700 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5700 survival associations across molecular data types. MIR5700 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5700 RNA expression–survival associations across cancer types. High MIR5700 expression shows unfavorable associations in LUAD, BRCA, LIHC, LUSC and UCEC, but favorable associations in ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR5700 RNA expression.
This table summarizes MIR5700 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5700. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5700 shows lower tumor expression in BRCA, PAAD and LUAD and higher tumor expression in HNSC and UCEC. The HNSC box plot shows higher MIR5700 RNA expression in tumor versus normal tissue (log2 FC = +0.230, t-test p = .002).
This table shows molecular features associated with MIR5700 in patient tissues and cancer cell lines. In patient samples, MIR5700 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
